Organ Preservation Value XVIVO is the only medical technology company dedicated to extending the life of all major organs, presenting a unique value proposition for organ preservation and transplant success that can be leveraged to engage transplant centers, hospitals, and funding bodies seeking improved outcomes.

Global Expansion With an international footprint and ongoing trials and partnerships, there are opportunities to target European, North American, and Latin American transplant networks, offering scalable solutions and collaborative study participation to drive adoption.

Clinical Evidence Recent ISHLT presentations of 12-month follow-up data from the NIHP2019 heart trial provide evidence-based talking points for procurement committees, researchers, and clinicians regarding performance, outcomes, and long-term patient quality of life.

Strategic Leadership Leadership changes and new deputies signal potential for strategic pivots or expansions; engage at the executive level to align on growth initiatives, partnerships, and possible M&A or distribution opportunities.

Partnership & Acquisition Footprint Historical partnerships and acquisitions (Contatti Medical, Avionord, Star Teams) indicate a track record of channel expansion and technology enhancement, suggesting opportunities to cross-sell, co-develop, or formalize distribution in target markets.